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Abstract
Background: The pathogenesis of atherosclerosis involves both hemostatic and inflammatory
mechanisms. Fibrinogen is associated with both risk of thrombosis and inflammation. A recent
meta-analysis showed that risk of coronary heart disease may increase 1.8 fold for 1 g/L of
increased fibrinogen, independent of traditional risk factors. It is known that fibrinogen levels may
be influenced by demographic, environmental and genetic factors. Epidemiologic and candidate
gene studies are available; but few genome-wide linkage studies have been conducted, particularly
in minority populations. The Strong Heart Study has demonstrated an increased incidence of
cardiovascular disease in the American Indian population, and therefore represents an important
source for genetic-epidemiological investigations.
Methods: The Strong Heart Family Study enrolled over 3,600 American Indian participants in
large, multi-generational families, ascertained from an ongoing population-based study in the same
communities. Fibrinogen was determined using standard technique in a central laboratory and
extensive additional phenotypic measures were obtained. Participants were genotyped for 382
short tandem repeat markers distributed throughout the genome; and results were analyzed using
a variance decomposition method, as implemented in the SOLAR 2.0 program.
Results: Data from 3535 participants were included and after step-wise, linear regression analysis,
two models were selected for investigation. Basic demographic adjustments constituted model 1,
while model 2 considered waist circumference, diabetes mellitus and postmenopausal status as
additional covariates. Five LOD scores between 1.82 and 3.02 were identified, with the maximally
adjusted model showing the highest score on chromosome 7 at 28 cM. Genes for two key
components of the inflammatory response, i.e. interleukin-6 and "signal transducer and activator of
transcription 3" (STAT3), were identified within 2 and 8 Mb of this 1 LOD drop interval respectively.
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other populations with LOD scores of 1.4 and 1.95.
Conclusion: In a minority population with a high prevalence of cardiovascular disease, strong
evidence for a novel genetic determinant of fibrinogen levels is found on chromosome 7 at 28 cM.
Four other loci, some of which have been suggested by previous studies, were also identified.
Background
Hypotheses concerning the pathogenesis of atherosclero-
sis have frequently included both hemostatic and inflam-
matory mechanisms. Fibrinogen levels are positively
associated with risk of thrombosis [1] and are also an
indicator of acute inflammatory response [2,3]. A recent,
large meta-analysis [4] concluded that for each 1 g/L
increase in plasma fibrinogen, individuals increase their
relative risk of coronary heart disease (CHD) by 1.8 after
adjustment for major cardiovascular disease (CVD) risk
factors. The Strong Heart Study (SHS) is an ongoing, lon-
gitudinal cohort study of CVD among American Indians
in three regions of the US, and began in 1988. The current
report is derived from the Strong Heart Family Study
(SHFS), an extension of the SHS, in which we have previ-
ously corroborated the ability of fibrinogen to predict
CVD events [5]. The above studies have identified fibrin-
ogen as a predictor of CVD independent of other standard
risk factors [6,7], however it is possible that fibrinogen
levels are simply correlated with other causal inflamma-
tory factors [8].
Fibrinogen levels are increased by many non-genetic fac-
tors, e.g. advancing age, smoking, obesity, oral contracep-
tive use and estrogen replacement therapy, whereas
moderate alcohol intake has been related to lower fibrin-
ogen levels [7,9,10]. Acquired metabolic conditions, e.g.
obesity, insulin resistance and type 2 diabetes also
increase fibrinogen levels [7,11]. Correlation between
fibrinogen and other hemostatic/inflammatory markers
has been demonstrated [12,13].
Moderate heritabilities of 34% and 37% were found in
two primarily Caucasian populations [9,14]. In our previ-
ous work, we demonstrated a heritability between 33 ±
6% and 44 ± 6% among the American Indian participants
of the SHFS [15]. Genome-wide linkage studies of fibrin-
ogen [16-18] are uncommon; but have identified a
number of suggestive quantitative trait loci (QTL). Poly-
morphisms of the fibrinogen gene have been extensively
investigated for their influence on circulating protein lev-
els [19-24].
Cardiovascular disease accounts for a large proportion of
mortality and morbidity in American Indian (AI) commu-
nities [25]. Since a substantial number of individuals with
CVD events have no previously identifiable risk factors
[6], it is important to develop the means to more accu-
rately predict CVD events. Although fibrinogen has been
shown to provide risk information independent of HDL,
total cholesterol and other typical cardiovascular risk fac-
tors [4,6]; a better understanding of the genetic and envi-
ronmental factors that influence variation in circulating
fibrinogen levels may improve our understanding of
CVD.
Methods
The Strong Heart Study (SHS) is a population-based,
cohort study of cardiovascular disease among American
Indians. The participating communities, study design, sur-
vey methods and laboratory techniques have been
described previously [26,27]. In 1998, the Strong Heart
Family Study, was initiated and participants 16 years and
older were recruited, without regard to disease status,
from multi-generational families, including index mem-
bers of the SHS cohort. All participants have given
informed consent for the genetic study of CVD and asso-
ciated risk factors, including the present study. In addi-
tion, approval for this study was obtained from relevant
tribal communities and institutional review boards.
The protocols for collection of all phenotypic data were
briefly described in previous publications [26]. Fibrino-
gen was measured with a coefficient of variation (CV) of <
8%, using the Clauss method [28] incorporating STA
Fibrinogen-5 reagents on the STA-R platform, both from
Diagnostica Stago. "Ever" smoking was defined as having
smoked at least 100 cigarettes during the lifetime and
"current" smoking (present, regular use of smoke
tobacco). "Current" and "ever" consumption of alcohol
was defined as having had at least 12 alcoholic beverages
in the last year or in past years, respectively.
The procedures for genotyping in the SHFS have been
described previously [29]. In brief, DNA was isolated from
fasting blood samples using organic solvents, and then
amplified in separate PCR reactions with primers specific
for short tandem repeat markers using the ABI PRISM
Linkage Mapping Set-MD10 Version 2.5 (Applied Biosys-
tems, Foster City, CA). PCR products were loaded into an
ABI PRISM 377 DNA sequencer for laser-based automated
genotyping. Analyses and assignment of the marker alleles
were done using computerized algorithms (Applied Bio-
systems). deCODE Genetics provided sex-averaged chro-Page 2 of 8
(page number not for citation purposes)
BMC Medical Genetics 2008, 9:77 http://www.biomedcentral.com/1471-2350/9/77mosomal maps (in units of Haldane centimorgans) for
this analysis. Pedigrees were screened with the PREST
(Pedigree Relationship Statistical Tests) [30] and Sim
Walk2 [31] programs for mendelian inconsistencies and
possible double recombinants. The above screening
resulted in less than 1% of all genotypes being excluded.
Statistical analysis
SAS, version 8.0, was used to screen covariates for statistical
significance using stepwise linear regression by center.
Univariate quantitative genetic analyses were used to par-
tition the phenotypic variance into its' additive genetic
and environmental components, using maximum likeli-
hood variance decomposition methods [32]. This
approach was implemented in the computer program
SOLAR, version 2.0 [32] and allows for an explicit test of
whether correlations among family members are in part
due to genetic effects.
The use of the variance component approach requires an
estimate of the identity-by-descent (IBD) matrix. We used
the Loki package [33], which employs a Markov chain
Monte Carlo stochastic procedure to compute the IBD
allele sharing at points throughout the genome condi-
tional on the genotype information available at neighbor-
ing points.
A total of 3535 SHFS participants were considered for
analysis (Arizona (AZ) = 1195, Dakota (DA) = 1158,
Oklahoma (OK) = 1182) after excluding those individuals
with missing covariate data and as indicated below to nor-
malize the phenotypic trait distribution. Because variance
components methods are sensitive to kurtosis [34], all
phenotypic outliers (here defined as any value more than
3 standard deviations from the mean) were removed prior
to analysis (number excluded varies by analysis, N < 15).
In addition, fibrinogen levels were natural log trans-
formed. All analyses were conducted separately for each
center and then on the combined data from all three cent-
ers. To maximize our power to detect genetic effects, a
minimally adjusted model (Model 1), incorporating age,
sex, age by sex and center covariates was analyzed first.
Secondary analyses considered adjustment for the linear
fixed effects of the covariates listed in Table 1, all of which
were identified from the published literature. Covariates
whose effects were significant (P < 0.05) in the initial
analysis in at least one Center were retained in the maxi-
mally adjusted model of all Centers (Model 2), even if the
significance levels decreased after inclusion of other cov-
ariates. This process resulted in the addition of waist cir-
cumference, the presence of ADA defined diabetes [35]
and postmenopausal status to Model 2. The addition of
current smoking as a covariate resulted in variable and
insignificant changes to the outcome, compared with
Model 2. We additionally confirmed the significance of
Model 2 covariates while accounting for family relation-
ships in SOLAR. Residuals were generated for both mod-
els (Model 1 and Model 2) and used in all subsequent
genetic analyses. Kurtosis values for fibrinogen were <
0.50 for all analyses.
The power of this study for each center was estimated by
simulations, assuming fully informative markers. The
simulations were based on a total heritability of the fibrin-
ogen phenotype either 25% or 50%. An estimate of the
power for all centers combined was determined by calcu-
lations based on the results from the individual centers,
due to the otherwise extremely high computational
demands for simulations.
Table 1: Descriptive characteristics of SHFS participants stratified by study recruitment center.1
AZ DK OK
Total sample size 2 N = 1195 N = 1158 N = 1182
Female N, (%) 747 (63) 684 (59) 700 (59)
Age, years Mean (± SD) 36.99 (16) 38.71 (17) 43.49 (17)
Fibrinogen, mg/dl Mean (± SD) 417.5 (87) 366.2 (80) 384.3 (84)
Diabetes 3 N (%) 391 (33) 162 (14) 241 (20)
Smoking,4Current N (%) 301 (25) 498 (43) 391 (33)
Waist, cm Mean (± SD) 111.5 (19) 99.4 (17) 101.6 (16)
Menopausal, Yes N (%) 187 (25) 180 (26) 259 (37)
Alcohol, Current N (%) 704 (59) 772 (67) 563 (48)
Total Cholest, mg/dl Mean (± SD) 174.5 (34.1) 181.4 (36.8) 185.9 (37.2)
LDL-Cholest, mg/dl Mean (± SD) 93.9 (25.9) 100.6 (31.0) 100.1 (30.4)
Triglycerides, mg/dl Mean (± SD) 170.1 (134.6) 156.9 (135.9) 172.3 (171.7)
Estrogen use, Yes N (%) 30 (4) 58 (8) 112 (16)
BMI, Kg/m2 Mean (± SD) 35.3 (8.4) 30.1 (6.7) 31.1 (6.7)
1 Percentages and means calculated only from those with available measurements. 2 Participants remaining after excluding age, waist and fibrinogen 
± 3SD and those with missing values. 3 Diabetes was determined using the American Diabetes Association criteria. 4 Smoking was defined as having 
had at least one hundred cigarettes.Page 3 of 8
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The statistical descriptors of fibrinogen and other covari-
ates are stratified by center and displayed in table 1. The
unadjusted fibrinogen levels were highest (417.5 mg/dl ±
87) in the Arizona center and the lowest (366.7 mg/dl ±
80) in the Dakota center. Individuals from the Arizona
Center had the highest prevalence of diabetes and obesity.
In contrast, SHFS participants from the Dakotas Center
had the highest prevalence of current smokers. The high-
est prevalence of menopause was in the Oklahoma
Center, perhaps since they were older on average.
Table 2 presents all suggestive (LOD ≥ 1.8) [36] genome-
wide, multipoint linkage scores of fibrinogen by center
and model. A QTL for fibrinogen (LOD = 3.02) was
detected in the Dakota Center on chromosome 7 at 28
centimorgans. The 1-cM LOD unit support interval
spanned 18 cM, from 17 to 35 cM (9,706,961 to
21,871,858 Mb P terminus).
Further suggestive evidence of linkage to fibrinogen was
observed in the Oklahoma center on chromosome 3 at
166 cM. The 1-cM LOD unit support interval spanned 15
centimorgans from 157 – 172 cM (144,754,119 to
164,001,645 Mb). In addition, we found suggestive evi-
dence of linkage to fibrinogen within all centers com-
bined to chromosome 6 at 122 cM. Of the suggestive LOD
scores, the only one that declined with adjustment was at
chromosome 6, 122 centimorgans, in the analysis includ-
ing all centers. In a post-hoc analysis, the only available
measure of inflammatory state, white blood cell count
(WBC), was included with previously described models to
adjust for inflammatory state. LOD scores in these analy-
ses showed essentially identical values for OK, model 2,
and DK, chromosome 7, model 1 of 2.51 and 2.81 respec-
tively. The LOD score for DK, chromosome 7, model 2
was reduced slightly to 2.41 and became insignificant
(0.51) for DK, chromosome 17, model 2.
While the α,β,γ fibrinogen genes are on chromosome 4,
the present study shows LOD scores for the DK center
only at 4q28, 155cM, ranging between 1.36 for Model 2
to 1.70 for Model 1; none of the other centers exhibited
LOD scores over 0.3 in this region.
Assuming a genome-wide heritability of 25%, power cal-
culations indicated an 80% power to detect a locus with a
LOD score > 3 for a locus contributing a minimum of
between 15 and 20% of total variance for each of the three
centers and 10% for all centers combined.
Discussion
Evidence for a pathophysiologic role of both thrombotic
and inflammatory influences on atherosclerosis continues
Table 2: Loci affecting fibrinogen levels.
Center/Model Adjusted LOD Score locus (± 1 LOD interval) physical locus Genes* within 1 LOD interval
OK
Model 2
2.47 Chr 3 loc 166 cm
(157 cm-172 cm)
144,754,119 to 164,001,645 133 Total
30 Labeled
Comparable LOD score from AZ = 0.07 DK = 0.06 ALL = 0.97
ALL
Model 1
2.10 Chr 6 loc 122 cm
(113 cm-126 cm)
104,686,675 to 125,240,989 143 Total
30 Labeled
Comparable LOD score from AZ = 1.67 DK = 0.63 OK = 0.83
DK
Model 1
2.81 Chr 7 loc 29 cm
(17 cm-36 cm)
9,706,961 to 22,141,263 54 Total
30 Labeled
Comparable LOD score from AZ = 0.02 OK = 0.00 ALL = 0.30
DK
Model 2
3.02 Chr 7 loc 28 cm
(17 cm-35 cm)
9,706,961 to 21,871,858 52 Total
30 Labeled
Comparable LOD score from AZ = 0.39 OK = 0.00 ALL = 0.55
DK
Model 2
1.82 Chr 17 loc 76 cm
(68 cm-93 cm)
45,179,978 to 66,077,271 240 Total
29 Labeled
Comparable LOD score from AZ = 0.08 OK = 0.00 ALL = 0.42
* As per the UCSC Genome Browser at http://genome.ucsc.edu/cgi-bin/hgGateway
* As per NCBI Map Viewer at http://www.ncbi.nlm.nih.gov/projects/mapview/maps.cgi.Page 4 of 8
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prospective studies involving over 150,000 participants
(without apparent disease at baseline) to predict future
CVD events is compelling, but not absolute, support for a
primary role in the development of atherosclerosis. [4]
The influence of fibrinogen would appear to be enhanced
among those with a high prevalence of diabetes, smoking
and other environmental influences [13], including the
presently described SHS population [5].
In addition to multiple environmental influences on
plasma fibrinogen levels [7,9] the effects of heritability
[9,14,15] and specific genetic variants (primarily involv-
ing the 3 fibrinogen gene cluster) are well established [19-
24,37]
While genetic polymorphisms in the fibrinogen genes are
found in diverse populations around the world [38,39],
and a role for variants of the α,β,γ fibrinogen genes has
been reported [9], there still appears to be substantial var-
iation due to unknown genetic effects [40]. Although the
Dakota center found modest genetic effects at the fibrino-
gen gene cluster on chromosome 4 (LOD 1.7), this was
not seen at either of the other two centers. Other investi-
gators have failed to demonstrate linkage to the fibrino-
gen gene loci in otherwise adequately powered studies
[18,41]., It would be of interest to determine if the com-
mon polymorphisms (such as the -455G/A variant of the
β gene promoter) seen in other populations [22] at this
locus are simply not well represented in these centers, or
whether they lack the typical effect size.
Suggestive evidence of linkage to novel loci was identified
in this study on chromosomes 3 (OK center), 6 (all cent-
ers combined) and both 7 and 17 (DK center). Our link-
age results at 3q22.2 (166 cM, closest to marker D3S1299)
are within 0.5 Mb of the angiotensin II receptor, type 1
gene (AGTR1, 149.4 Mb-150.1 Mb) and this gene is thus
well within the 1 LOD interval (144.8 Mb-169.8 Mb). The
angiotensin converting enzyme I (ACE1) gene is also
located within the 1 LOD interval of our suggestive locus
at chromosome 17 (68 cM to 93 cM) [42] Although
AGTR1, ACE1, and fibrinogen all have relevance to CVD,
there is no readily apparent physiologic connection
between fibrinogen levels and the renin-angiotensin-sys-
tem (RAS). While the RAS is an important factor in the
regulation of blood pressure, and fibrinogen is often ele-
vated in the presence of hypertension, we are unaware of
any evidence that increased fibrinogen preceeds or influ-
ences the development of hypertension. It is possible that
a genetic variant in this locus simultaneously controlling
expression of both fibrinogen and RAS genes.
Findings of Ding et al [41] support our results at 6q21, see
Table 3. There are 143 genes within the 1 LOD confidence
limits of the locus at 6q21 (122 cM, closest to marker
D6S303); but none have obvious relationships with
fibrinogen.
Within the 1 LOD drop interval at 7p21.1 (28 cM, closest
to marker D7S507), the integrin beta-8 (ITGB8) gene is
located at 31 cM. This gene is related to ITGB3 (see below)
and shares similar important relationships with trans-
forming growth factor, beta 1 (TGFB1) and other ele-
ments of the immune system [43,44]. The interleukin-6
gene (IL6) is located 2 Mb beyond the 1 LOD drop inter-
val on 7p21 at 22.7 Mb, closest to deCODE markers at
41.69 cM. Zhang et al [45] have shown a correlation
between IL6 and fibrinogen levels (r = 0.22, p < 0.0001).
Not all [24], but some IL6 polymorphisms are known to
affect fibrinogen levels [46]. The central role of IL6 in
inflammatory physiology would make this a strong candi-
date for effects on fibrinogen as an acute phase reactant,
although the fact that the DK LOD score at this locus was
Table 3: Other studies showing genetic effects on fibrinogen levels.
Variant, and/or locus Physical locus LOD score or p-value Reference
Chromo 1p31.3 rs6683832 62,988,925 5.6 × 10-5 Yang et al [41]
1p31 Leptin receptor (LEPR) haplotype block including: rs3790432, 
rs1137101, rs1805096
65,764,013 – 65,873,699 0.005 Zhang et al [45]
Chromo 2, 55.5 cM (African Americans) 36,013,772 – 36,214,030 LOD = 2.14 Ding et al [41]
Chromo 2, q36.3 rs1273819 227,307,918 LOD = 2.4 Yang et al [41]
Chromo 6, 136 cM (African Americans) 134,596,514 – 134,796,754 LOD = 1.43 Ding et al [41]
Chromo 12, 152.16 cM fibrinogen and CRP (bivariate) (African Americans) 127,228,944 – 127,429,321 LOD = 3.44 Ding et al [41]
Chromo 12q14.2 rs10506540 65,699,364 2.2 × 10-5 Yang et al [41]
Chromo 12q24 D12S79 – D12S1718 114,444,811 – 116,237,121 LOD = 2.1 Soria et al [18]
Chromo 14 rs974673 33,550,265 3.1 × 10-5 Yang et al [41]
Chromo 14q11 D14S72 – D14S50 20,340,828 – 21,525,933 LOD = 3.12 Soria et al [18]
Chromo 17, 96 cM 67,937,333 – 68,137,655 LOD = 1.4 Yang et al [51]
Chromo 17, 93 cM (African Americans) 66,019,673 – 66,220,040 LOD = 1.95 Ding et al [41]
Chromo 21, 13.05 cM fibrinogen and CRP 
(bivariate) (Non-Hispanic Whites)
20,322,875–20,523,182 LOD = 3.03 Ding et al [41]Page 5 of 8
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tory marker (WBC) suggests inflammatory stimuli are not
the sole determinants of fibrinogen levels.
Our findings at chromosome 17, 76 cM (nearest marker
D17S1607) are in close proximity to the LOD of 1.4
found by Yang et al [47] at 96 cM (on the Marshfield
map). The growth hormone (GH1) lies within the 1 LOD
drop interval and exerts an influence on fibrinogen levels
[48]. The integrin, beta-3 (ITGB3) and "signal transducer
and activator of transcription 3" (STAT3) genes both
reside within 3 and 8 Mb respectively of this 17q23.3
interval and both are known to affect baseline and acute
phase fibrinogen expression [41,49].
These current findings derive from specific subsets of the
North American Indian population and each center of the
study analyzes a group essentially the same size as that
reported from the Framingham Heart Study [16]. One
might expect more homogeneous findings among these
American Indian populations; but they are separated by
about 1,000 Km and have distinct language and cultural
characteristics. The SHS has found similar diversity
between centers in the analysis of other phenotypes. The
lack of apparent effect in the AZ and OK centers of the
fibrinogen gene cluster at chromosome 4q28, in compar-
ison to Caucasian populations, further highlights appar-
ent differences between ethnic groups. No overlapping
linkage regions with LOD scores over 1.3 were found in
comparing African Americans and non-Hispanic whites in
the GENOA study [41], although limitations of power
may have been a factor. The relative lack of consistency in
linkage study findings has been commented on before
and our findings are consistent with this [50]. Perhaps
unappreciated environmental effects are present, which
have not been fully accounted for in the adjustment strat-
egies used by various investigators.
Strengths of this study include the population-based
recruitment with large numbers of participants analyzed
and the large, multi-generational families recruited. Our
calculations indicate an 80% power to identify a QTL with
a LOD score of more than 3 contributing at least 20% of
the total phenotypic variance in any center. In spite of the
above-mentioned diversity of findings, the genetic back-
ground of the populations are likely to be more uniform
than population-based studies from urban areas. The pro-
spective collection of a very well characterized phenotype,
including many demographic, environmental and physi-
ologic parameters is another strength.
Although the large size of the families in this study
increases the power to detect genetic effects, it may also
magnify the effects of uncommon polymorphisms in a
particular family. This should be minimized by the fact
that recruitment for the family study was not based on the
presence or history of CVD and the fact that 13.6% of the
family study participants were also members of the origi-
nal, population-based cohort.
Conclusion
In a minority population with a high prevalence of cardi-
ovascular disease, strong evidence for a novel genetic
determinant of fibrinogen levels is found on chromosome
7 at 28 cM. Four other loci, some of which have been sug-
gested by previous studies, were also identified. Fibrino-
gen is of particular interest since it may act through two
independent pathophysiologic mechanisms, i.e. throm-
bosis and inflammation. A better understanding of the
genetic determinants of fibrinogen levels and how they
influence the development of atherosclerosis and its com-
plications will assist in fashioning better preventive and
treatment strategies for this very serious public health
problem.
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